Featured News See All October 21, 2024 REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 September 17, 2024 REGENXBIO Appoints Mitchell Chan as Chief Financial Officer September 3, 2024 REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect Year All202420232022202120202019201820172016201520142013201220112009 Jun 05, 2024 REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference May 10, 2024 REGENXBIO to Participate in Upcoming Investor Conferences May 08, 2024 REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights May 01, 2024 REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights Apr 24, 2024 REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit Mar 28, 2024 REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD Mar 27, 2024 REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
May 08, 2024 REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
May 01, 2024 REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
Apr 24, 2024 REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Mar 28, 2024 REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD